Literature DB >> 15845609

MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration.

Tongguang Wang1, Zhong Pei, Wei Zhang, Bin Liu, Robert Langenbach, Christopher Lee, Belinda Wilson, Jeffrey M Reece, David S Miller, Jau-Shyong Hong.   

Abstract

The importance of cyclooxygenase-2 (COX-2) in mediating Parkinson's disease (PD) was suggested in reports, indicating that COX-2 selective inhibitors or genetic knockout reduce 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic (DA) neurotoxicity in a mouse model of PD. However, cell types and mechanisms underlying the activation of COX-2 have not been clearly elucidated in these animal studies. Using primary neuron-glia cultures, we aimed to determine 1) whether microglia participate in 1-methyl-4-phenylpryridinium (MPP)-induced COX-2 activation and 2) whether the activation of COX-2 contributes to subsequent neurotoxicity. MPP, in a concentration-dependent manner, increased prostaglandin E2 (PGE2) production in mixed neuron-microglia cultures but not in enriched neuron, microglia, or astroglia cultures nor in mixed neuron-astroglia cultures. MPP-induced PGE2 increase was completely abolished by treatment with DuP697, a COX-2 selective inhibitor. DuP697 also significantly reduced MPP-induced DA neurotoxicity as determined by DA uptake assay. Immunocytochemistry and confocal microscopy studies showed enhanced COX-2 expression in both microglia and neurons after MPP treatment. However, neuronal increase in COX-2 expression was not totally dependent on the production of PGE2 from microglia, since microglia deficient in COX-2 only attenuated, but did not completely block, MPP-increased PGE2 production in mixed neuron-microglia cultures, suggesting that part of PGE2 production was originated from neurons. Together, these results indicate that MPP-induced COX-2 expression and subsequent PGE2 production depend on interactions between neurons and microglia. Microgliosis may also be responsible for the COX-2 activation in neurons, leading to the enhanced DA neurotoxicity, which, in turn, reinforces microgliosis. Thus inhibition of microgliosis and COX-2 activity may stop this vicious circle and be valuable strategies in PD therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845609     DOI: 10.1096/fj.04-2457fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  30 in total

Review 1.  Intercellular (mis)communication in neurodegenerative disease.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

Review 2.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

3.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

Review 4.  Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases.

Authors:  Jogen Atone; Karen Wagner; Kenji Hashimoto; Bruce D Hammock
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-11-05       Impact factor: 3.072

Review 5.  Antioxidant gene therapy against neuronal cell death.

Authors:  Juliana Navarro-Yepes; Laura Zavala-Flores; Annadurai Anandhan; Fang Wang; Maciej Skotak; Namas Chandra; Ming Li; Aglaia Pappa; Daniel Martinez-Fong; Luz Maria Del Razo; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Pharmacol Ther       Date:  2013-12-12       Impact factor: 12.310

6.  The effect of docosahexaenoic Acid on visual evoked potentials in a mouse model of Parkinson's disease: the role of cyclooxygenase-2 and nuclear factor kappa-B.

Authors:  Ozlem Ozsoy; Gamze Tanriover; Narin Derin; Nimet Uysal; Necdet Demir; Burcu Gemici; Ceren Kencebay; Piraye Yargicoglu; Aysel Agar; Mutay Aslan
Journal:  Neurotox Res       Date:  2011-01-14       Impact factor: 3.911

7.  PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target.

Authors:  Abdullah Shafique Ahmad; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

8.  Control protocol for robust in vitro glial scar formation around microwires: essential roles of bFGF and serum in gliosis.

Authors:  Vadim S Polikov; Eric C Su; Matthew A Ball; Jau-Shyong Hong; William M Reichert
Journal:  J Neurosci Methods       Date:  2009-05-15       Impact factor: 2.390

9.  Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.

Authors:  Anna L Bartels; Klaus L Leenders
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

10.  Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia.

Authors:  Johannes C M Schlachetzki; Bernd L Fiebich; Elisabeth Haake; Antonio C P de Oliveira; Eduardo Candelario-Jalil; Michael T Heneka; Michael Hüll
Journal:  J Neuroinflammation       Date:  2010-01-11       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.